181.75 +0.16 (0.09%)
After hours: 4:49PM EDT
|Bid||180.21 x 200|
|Ask||181.90 x 100|
|Day's Range||181.40 - 184.04|
|52 Week Range||152.16 - 201.23|
|PE Ratio (TTM)||67.51|
|Forward Dividend & Yield||5.28 (2.91%)|
|1y Target Est||N/A|
On March 7, 2018, Teva Pharmaceutical (TEVA) with Teva Canada and Xenon Pharmaceuticals (XENE) entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012 for the pain drug TV-45070. During Xenon Pharmaceuticals’ 2017 earnings results release, it announced the agreement termination news. On the day, TEVA stock rose ~0.8%, while Xenon stock rose ~7%. Teva Pharmaceutical stated that it was no longer interested in the development of TV-45070.
Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.
But what is clear is that in the not too distant future, PCSK9 inhibitors will be priced in a way that will be palatable to payers thereby making this class of important drugs available to those whose lives can be saved or prolonged by them.
Amgen would be better off stringing together small deals, rather than attempting a megamerger, an analyst suggested Monday.
In March 2017, Merck (MRK) and Eisai entered into a collaboration to jointly develop and commercialize Lenvima, a TK (tyrosine kinase) inhibitor developed by Eisai. Merck and Eisai entered into the collaboration to jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s Keytruda. Lenvima is approved as a monotherapy for the treatment of thyroid cancer.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Assessing Amgen Inc’s (NASDAQ:AMGN) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Drugmakers tried just about every move under the sun to nurture sales of its products -- pharmacy coupons for patients, exclusive deals with insurers, even selling a medicine’s patent to a Native American ...